When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease.

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

A groundbreaking trial shows Akero's drug can reverse cirrhosis, defying expectations--analysts say the upside could be massive.

Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...